Scotland’s Glox Therapeutics raises €4.9M to combat antimicrobial resistance
Glasgow-based Glox Therapeutics, a company that aims to advance its precision antibiotic therapies, focusing on naturally occurring bacteriocins, has secured £4.3M (approximately €4.93M) in a seed round of funding.